Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma(†)

BACKGROUND: The phase III RAINBOW trial demonstrated that the addition of ramucirumab to paclitaxel improved overall survival, progression-free survival, and tumor response rate in fluoropyrimidine–platinum previously treated patients with advanced gastric/gastroesophageal junction (GEJ) adenocarcin...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Batran, S.-E., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O. N., Kim, T.-Y., Cunningham, D., Rougier, P., Muro, K., Liepa, A. M., Chandrawansa, K., Emig, M., Ohtsu, A., Wilke, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803452/
https://www.ncbi.nlm.nih.gov/pubmed/26747859
http://dx.doi.org/10.1093/annonc/mdv625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803452/
https://www.ncbi.nlm.nih.gov/pubmed/26747859
http://dx.doi.org/10.1093/annonc/mdv625

Ejemplares similares